Gensia Sicor Files Lawsuit Against American

Pharmaceutical Partners IRVINE, Calif. (PROTEXT) - Gensia Sicor Inc. (Nasdaq: GNSA) today announced that its wholly owned subsidiary, Gensia Sicor Pharmaceuticals, Inc., filed a lawsuit on April 23, 1999 in the Superior Court of California for Orange County against American Pharmaceutical Partners ("APP") for breach of contract, breach of the implied covenant of good faith and fair dealing, unfair competition and declaratory relief. The suit alleges that APP has breached a distributorship agreement for certain Gensia Sicor Pharmaceuticals products by, among other things, acquiring and operating a business which competes with Gensia Sicor Pharmaceuticals with respect to some of the same products. The Company is seeking damages in excess of $10 million in addition to a declaration that the Company has no obligation or liability to APP. Gensia Sicor Inc. is a vertically integrated pharmaceutical company with proven expertise in the development, manufacturing and marketing of injectable pharmaceuticals and in the production of specialty bulk drug substances utilizing synthesis or fermentation. The company is focused on the worldwide oncology and injectable pharmaceutical markets. Gensia Sicor's commercial pharmaceutical businesses include Gensia Sicor Pharmaceuticals, Inc., a California-based manufacturer and marketer of multisource injectable drugs, SICOR-Societa Italiana Corticosteroidi S.p.A. and Diaspa S.p.A., both of Milan Italy, and Sicor de Mexico, S.A. de C.V. in Toluca, Mexico all which produce specialty bulk drug substances, and Lemery, S.A. de C.V. in Mexico City which manufactures injectable and oral finished multisource drug products. Gensia Sicor's company offices are located in Irvine, CA. This press release contains forward looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward looking statements, including whether Gensia Sicor's suit will be upheld in a court of law, whether Gensia Sicor will receive any compensatory damages and those matters set forth in the risk factors section of Gensia Sicor's filings on Forms 10-K and 10-Q with the Securities and Exchange Commission. These forward looking statements represent the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward looking statements. For more information on the Company, visit Gensia Sicor's new web site at www.gensiasicor.com. News releases are also available at no charge through PR Newswire's News On-Call fax service. For a menu of available news releases or to retrieve a specific release made by Gensia Sicor, call 800-758-5804, extension 354050. Please retain these numbers for future reference. ots Original Text Service: Gensia Sicor Inc. Internet: http://www.newsaktuell.de Contact: Laurie W. Little of Gensia Sicor Inc., 949-455-4879; or Carolyn Bass or Jim Byers, 415-296- 7383, or Patricia Walsh or Mark Owen, 212-850-5600, all of Morgen-Walke Associates, Inc. for Gensia Sicor Inc. Company News On-Call: http://www.prnewswire.com/comp/354050.html or fax, 800- 758-5804, ext. 354050 Web site: http://www.gensia.com Web site: http://www.gensiasicor.com Subscribers please note that material bearing the slug "PROTEXT" is not part of CTK's news service and is not to be published under the "CTK" slug. Protext is a commercial service providing distribution of press releases from clients, who are identified in the text of Protext reports and who bear full responsibility for their contents. PROTEXT